MYL4
ENSG00000198336
Target class
Unclassified protein
Chromosome
17
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MYL4
- Gene name
- Myosin light chain 4
- Gene symbol
- MYL4
- Protein name
- Myosin light chain 4 (Myosin light chain 1, embryonic muscle/atrial isoform) (Myosin light chain alkali GT-1 isoform)
- ALC1
- AMLC
- GT1
- PRO1957
- Gene biotype
- Protein coding
- Gene family
- Myosin light chains, class 1
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 12
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 2,518.25
- Tissue specificity (Gini)
- 0.971
- Tissue specificity (tau)
- 0.999
- KEGG gene identifiers
- hsa:4635
- Reactome pathways
- R-HSA-390522
- Protein interaction confidence
- 0.815077
- Protein interaction partners
- 39
- End position
- 47227683
- Start position
- 47200446
- Chromosome
- 17
- Strand
- Forward
- Plasma membrane
- Tissue specificity (tau)
- 0.99912
- Expression inequality (Gini)
- 0.971359
Expression in transcripts per million
- Heart - Atrial Appendage
- 2,518.25
- Whole Blood
- 33.08
- Heart - Left Ventricle
- 29.61
- Testis
- 19.04
- Thyroid
- 8.84
Expression in transcripts per million
- Heart - Atrial Appendage2,518.25
- Whole Blood33.08
- Heart - Left Ventricle29.61
- Testis19.04
- Thyroid8.84
- Spleen1.56
- Adipose - Visceral (Omentum)1.49
- Lung1.49
- Adipose - Subcutaneous1.22
- Nerve - Tibial1.22
- Artery - Coronary1.19
- Stomach1.03
- Breast - Mammary Tissue0.99
- Artery - Tibial0.96
- Artery - Aorta0.74
- Esophagus - Gastroesophageal Junction0.69
- Cells - EBV-transformed lymphocytes0.67
- Esophagus - Muscularis0.67
- Prostate0.66
- Uterus0.65
- Bladder0.64
- Muscle - Skeletal0.62
- Small Intestine - Terminal Ileum0.62
- Vagina0.59
- Kidney - Medulla0.59
And 29 more, listed on the interactive page.
- GO:0002026
- GO:0006936
- GO:0060048
- GO:0005829
- GO:0031672
- GO:0003785
- GO:0051015
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator